PRKCG — Protein Kinase C Gamma

Migration, Crosslink

📖

PRKCG — Protein Kinase C Gamma

active

wiki page Created: 2026-04-02T07:19:17 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-prkcg

📖 Wiki Page

gene2761 wordssynced 2026-04-02

PRKCG — Protein Kinase C Gamma

Introduction

PRKCG (Protein Kinase C Gamma) encodes Protein Kinase C gamma (PKCγ), a neuron-specific serine/threonine kinase belonging to the PKC family of protein kinase C isoforms. PKCγ is unique among PKC isoforms in that its expression is restricted primarily to [neurons](/entities/neurons), particularly in the cerebellum, [hippocampus](/brain-regions/hippampus), and [cerebral cortex](/brain-regions/cortex). This targeted expression pattern makes PKCγ particularly important in neuronal function and disease processes affecting these brain regions.

...

PRKCG — Protein Kinase C Gamma

Introduction

PRKCG (Protein Kinase C Gamma) encodes Protein Kinase C gamma (PKCγ), a neuron-specific serine/threonine kinase belonging to the PKC family of protein kinase C isoforms. PKCγ is unique among PKC isoforms in that its expression is restricted primarily to [neurons](/entities/neurons), particularly in the cerebellum, [hippocampus](/brain-regions/hippampus), and [cerebral cortex](/brain-regions/cortex). This targeted expression pattern makes PKCγ particularly important in neuronal function and disease processes affecting these brain regions.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PRKCG</th></tr>
<tr><td>Gene Symbol</td><td>PRKCG</td></tr>
<tr><td>Full Name</td><td>Protein Kinase C Gamma</td></tr>
<tr><td>Chromosome</td><td>19q13.42</td></tr>
<tr><td>NCBI Gene ID</td><td>[5586](https://www.ncbi.nlm.nih.gov/gene/5586)</td></tr>
<tr><td>OMIM</td><td>176980</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000156508</td></tr>
<tr><td>UniProt ID</td><td>[P05129](https://www.uniprot.org/uniprot/P05129)</td></tr>
<tr><td>Protein Class</td><td>Serine/Threonine Kinase</td></tr>
<tr><td>Expression</td><td>Neuron-specific</td></tr>
<tr><td>Associated Diseases</td><td>Spinocerebellar Ataxia Type 14, Alzheimer's Disease, Parkinson's Disease, Neuropathic Pain</td></tr>
</table>
</div>

Overview

Mermaid diagram (expand to render)

The PRKCG gene has emerged as an important player in neurodegenerative disease research. Its encoded protein, PKCgamma, participates in numerous critical neuronal processes including [synaptic plasticity](/mechanisms/synaptic-plasticity), learning and memory, ion channel regulation, and pain signaling. Pathogenic mutations in PRKCG cause spinocerebellar ataxia type 14 (SCA14), an autosomal dominant progressive cerebellar ataxia characterized by gait instability, dysarthria, and oculomotor abnormalities.[@schutt2019] Additionally, dysregulation of PKCgamma signaling has been imp["@jiang2019"]licated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimer-disease) and [Parkinson's disease](/diseases/parkinson-disease), as well as in chronic neuropathic pain conditions.

This page provides comprehensive information about PRKCG gene structure, PKCgamma protein function, disease associations, molecular mechanisms, therapeutic implications, and current research directions.

Gene Structure and Evolution

Genomic Organization

The PRKCG gene is located on chromosome 19q13.42, spanning approximately 32.5 kb of genomic DNA. The gene consists of 17 exons encoding a 697-amino acid protein. The gene promoter contains regulatory elements that drive neuron-specific expression, including binding sites for neuronal transcription factors such as Ngn2 and NeuroD1.

Protein Domain Structure

PKCγ contains several functional domains:

Auto-inhibitory pseudosubstrate segment (residues 19-31): Maintains the kinase in an inactive conformation by occupying the active site

C1 domain (residues 31-91): Binds diacylglycerol (DAG) and phorbol esters in the presence of Ca²⁺

C2 domain (residues 159-292): Mediates Ca²⁺-dependent phospholipid binding (phosphatidylserine)

Kinase domain (residues 346-620): The catalytic core with ATP-binding site

Regulatory region (N-terminal): Contains the pseudosubstrate and C1/C2 domains

The full-length PKCγ (89 kDa) undergoes proteolytic cleavage to generate a constitutively active kinase fragment (PKMγ), which is involved in maintaining long-term synaptic changes.

Molecular Function

PKC Signaling Cascade

PKCγ is a key mediator of the diacylglycerol (DAG) signaling pathway. Upon neuronal activation:

Second messenger generation: G-protein-coupled receptors (GPCRs) activate phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP₂) into DAG and inositol trisphosphate (IP₃)

PKC activation: DAG binds the C1 domain of PKCγ in the presence of Ca²⁺,Releasing the auto-inhibitory pseudosubstrate

Substrate phosphorylation: Active PKCγ phosphorylates numerous substrate proteins

Signal termination: Dephosphorylation and protein kinase degradation terminate the signal

Key Substrates and Cellular Functions

PKCγ phosphorylates numerous substrates involved in:

| Substrate | Function | Effect of Phosphorylation |
|----------|----------|--------------------------|
| NMDA receptor | Glutamate receptor | Modulation of channel activity |
| AMPA receptor | Glutamate receptor | Synaptic trafficking |
| DARPP-32 | Dopamine signaling | Enhanced signaling |
| MARCKS | Actin binding | Cytoskeletal reorganization |
| Tau | Microtubule stability | Altered function |
| APP | Amyloid precursor | Proteolytic processing |

Neuronal Processes Affected

Synaptic Plasticity

PKCγ plays a critical role in both [long-term potentiation (LTP)](/mechanisms/long-term-potentiation) and long-term depression (LTD), the cellular substrates of learning and memory:

LTP induction: PKCγ activation contributes to the early phase of LTP by phosphorylating NMDA and AMPA receptors, enhancing their conductance
Late-phase LTP: PKC-mediated transcription of synaptic proteins
LTD induction: PKCγ activation can also trigger internalization of AMPA receptors during LTD

The generation of constitutively active PKMγ (a cleavage product of PKCγ) has been implicated in maintaining late-phase LTP and memory consolidation.

Ion Channel Regulation

PKCγ modulates several ion channels critical for neuronal excitability:

NMDA receptors: Phosphorylation enhances Ca²⁺ permeability
AMPA receptors: Regulation of receptor trafficking
Voltage-gated Ca²⁺ channels: Modulation of channel gating
Sodium channels: Regulation of inactivation

Neuronal Development

During development, PKCγ participates in:

Axon guidance
Dendritic patterning
Synapse formation
Cerebellar Purkinje cell maturation

Disease Associations

Spinocerebellar Ataxia Type 14 (SCA14)

SCA14 is an autosomal dominant neurodegenerative disorder caused by pathogenic mutations in the PRKCG gene. It is characterized by progressive cerebellar dysfunction.

Clinical Features

Onset: Typically adult-onset (30-50 years), but can be childhood or late-onset
Gait ataxia: Progressive unsteadiness
Dysarthria: Slurred speech
Oculomotor abnormalities: Nystagmus, slowed saccades
Cognitive impairment: Some patients develop mild cognitive deficits
Peripheral neuropathy: In some cases
Parkinsonism: Rare feature in some families

Pathogenic Mutations

Over 25 pathogenic mutations have been identified in PRKCG. Recent structural analyses have identified mutation hot spots and mechanisms of pathogenesis:

| Mutation | Domain | Year Identified |
|----------|--------|-----------------|
| R41P | Pseudosubstrate | 2005 |
| H101Y | C1 domain | 2005 |
| G118R | C1 domain | 2011 |
| C150F | C1 domain | 2015 |
| D219N | C2 domain | 2019 |
| P236L | C2 domain | 2020 |
| G317R | Kinase domain | 2022 |
| R341C | Kinase domain | 2006 |

Most mutations cause protein misfolding, impaired membrane translocation, or altered substrate recognition.

Pathogenesis Mechanisms

SCA14 mutations cause neurodegeneration through multiple mechanisms:

Proteotoxic stress: Misfolded protein accumulation triggers ER stress

Impaired translocation: Defective C1 domain affects membrane targeting

Altered substrate specificity: Mutations change kinase activity

Cellular energy deficit: Mutant PKCγ impairs mitochondrial function

Oxidative stress: Increased ROS production in Purkinje cells

Synaptic dysfunction: Impaired parallel fiber-Purkinje cell synapses

Alzheimer's Disease

PKCγ is intimately involved in AD pathogenesis through multiple pathways:

Amyloid Precursor Protein (APP) Processing

PKCγ regulates α-secretase activity, promoting the non-amyloidogenic APP processing pathway:

PKC activation increases α-secretase-mediated APP cleavage
This production of sAPPα has neuroprotective effects
Reduces Aβ peptide generation

Tau Phosphorylation

PKCγ can phosphorylate tau protein at multiple sites:

Alters tau-microtubule interactions
May promote tau aggregation
Contributes to neurofibrillary tangle formation

A key study showed that PRKCG knockdown enhances tau phosphorylation at Thr181 and Thr231, linking PKCγ to neurofibrillary pathology.

Synaptic Dysfunction

PKCγ dysregulation contributes to:

Impaired LTP
Synaptic protein loss
Dendritic spine reduction
Memory deficits

Parkinson's Disease

While less well-characterized than in AD, PKCγ involvement in PD includes:

Regulation of α-synuclein phosphorylation
Mitochondrial function
Dopaminergic neuron survival
Lewy body formation pathways

Neuropathic Pain

PKCγ in spinal cord dorsal horn neurons mediates chronic pain states:

Central sensitization
NMDA receptor phosphorylation
Induction of pain hypersensitivity
PKCγ knockout mice show reduced pain behaviors

Expression Pattern

Brain Regional Distribution

PRKCG shows neuron-specific expression with highest levels in:

Cerebellum: Highest expression in Purkinje cells

Hippocampus: High in CA1-CA3 pyramidal neurons

Cerebral cortex: Layer II-IV pyramidal neurons

Basal ganglia: Striatal medium spiny neurons

Spinal cord: Dorsal horn neurons

Cellular Expression

Neurons: Pyramidal cells, Purkinje cells, interneurons
Non-neuronal: Not expressed in glia under normal conditions

Therapeutic Implications

Target for Neurodegenerative Diseases

PKCγ represents a potential therapeutic target for:

AD modulators: PKC activators in development

SCA14 treatment: Gene therapy approaches

Pain management: PKCγ inhibitors for chronic pain

Clinical Trials and Drug Development

Several PKC-targeted approaches have been explored:

Bryostatin: PKC activator in AD trials
PKC peptides: Peptide inhibitors
Gene therapy: AAV-based PRKCG knockdown

Animal Models

Knockout Mouse

PKCγ knockout mice show:

Impaired motor learning
Abnormal Purkinje cell morphology
Reduced cerebellar LTD
Enhanced sensitivity to neurotoxins

Transgenic Models

SCA14 transgenic models recapitulate:

Progressive ataxia
Purkinje cell loss
Motor dysfunction

Research Directions

Current Areas of Investigation

Structural biology: Mutant protein structures

Gene therapy: CRISPR/Cas9 approaches

Biomarkers: Disease progression markers

Stem cell models: iPSC-derived neurons

Unresolved Questions

Why are Purkinje cells selectively vulnerable?
How do different mutations cause variable phenotypes?
Can PKC modulation slow disease progression?

Diagnosis and Genetic Testing

Diagnostic Approach

Diagnosis of PRKCG-related disorders involves a multi-step approach:

Clinical evaluation: Comprehensive neurological examination assessing gait, coordination, speech, and cognitive function

Neuroimaging: MRI to evaluate cerebellar atrophy, particularly in the vermis

Genetic testing: Targeted PRKCG sequencing or multi-gene panels

In silico analysis: Prediction tools for variant pathogenicity

Neurophysiology: EMG, nerve conduction studies when peripheral neuropathy is suspected

Differential Diagnosis

SCA14 must be distinguished from other spinocerebellar ataxias:

| Disorder | Distinguishing Features |
|---------|----------------------|
| SCA1 | Fast progression, bulbar involvement |
| SCA2 | Slow saccades, hyporeflexia |
| SCA3 | Parkinsonism, dystonia |
| SCA6 | Pure cerebellar, episodic |
| SCA14 | Adult onset, myoclonus possible |

Genetic Counseling

PRKCG mutations follow an autosomal dominant inheritance pattern with:

50% transmission risk to offspring
Variable expressivity even within families
Possible anticipation in some families with earlier onset in successive generations
Reduced penetrance in rare cases where carriers remain asymptomatic
De novo mutations account for approximately 10% of cases

Treatment and Management

Current Therapeutic Approaches

Currently, no disease-modifying therapy exists for SCA14. Treatment is supportive and symptomatic:

| Symptom | Treatment | Evidence Level |
|---------|-----------|----------------|
| Ataxia | Physical therapy, balance training | Moderate |
| Dysarthria | Speech therapy | Moderate |
| Tremor | Propranolol, clonazepam | Limited |
| Myoclonus | Clonazepam, valproate | Limited |
| Cognitive issues | Acetylcholinesterase inhibitors | Anecdotal |
| Depression | SSRIs, counseling | Standard |

Emerging Therapies

Several innovative approaches are under active investigation:

AAV gene therapy: Adeno-associated viral vector delivery of wild-type PRKCG to restore functional protein expression in Purkinje cells. Early pre-clinical studies show promise in mouse models.

RNAi-mediated knockdown: Allele-specific silencing of mutant PRKCG transcripts using siRNA or shRNA approaches, sparing the wild-type allele.

CRISPR/Cas9 editing: Precise correction of pathogenic mutations using base editing or prime editing techniques. Current challenges include delivery to neurons and efficiency.

Protein folding correctors: Small molecule compounds that improve mutant PKCγ folding and trafficking, reducing ER stress and restoring function.

Stem cell transplantation: Replacement of lost Purkinje cells using embryonic stem cell-derived or iPSC-derived progenitors. Studies in animal models show functional integration.

Symptomatic Management Guidelines

Physical therapy: Gait training, balance exercises, fall prevention
Occupational therapy: Adaptive devices, home modifications
Speech therapy: Communication strategies, swallowing assessment
Nutritional support: Dysphagia management, weight maintenance
Psychological support: Counseling for quality of life, family support

Biochemical Properties

Enzyme Kinetics

PKCγ exhibits typical protein kinase kinetics essential for its function:

Km for ATP: Approximately 10 μM in standard conditions
Vmax: Approximately 500 pmol/min/mg protein
Optimal pH: 7.0-7.5 for maximal activity
Optimal temperature: 30°C for enzymatic function
Mg²⁺ requirement: Essential cofactor for phosphate transfer

Regulation Mechanisms

PKCγ is regulated at multiple levels ensuring proper signaling:

Transcriptional regulation: Neuronal activity-dependent expression via CREB and other transcription factors

Post-translational modifications: Phosphorylation at multiple sites controls activity

Protein-protein interactions: RACK proteins anchor PKCγ at appropriate membranes

Subcellular localization: Dynamic translocation between cytosol and membrane

Proteolytic processing: Generation of constitutively active PKMγ fragment

Post-Translational Modifications Table

| Modification | Site | Functional Effect |
|--------------|------|-----------------|
| Phosphorylation | T514 (activation loop) | Required for kinase activity |
| Phosphorylation | S675 (C-terminal) | Autophosphorylation, stability |
| Ubiquitination | K299 | Protein degradation |
| Oxidation | Multiple cysteines | Reversible inactivation |
| Palmitoylation | Cys residues | Membrane association |

Protein-Protein Interactions

Key Interacting Proteins

PKCγ interacts with several critical neuronal proteins:

RACK1 (Receptor for Activated C Kinase 1): Anchors PKCγ at membranes and scaffolding

PDK1: Phosphorylates the activation loop residue T514

PKA: Cross-talk in neuronal signaling pathways

Calmodulin: Ca²⁺-dependent regulation of activity

NMDA receptor subunits (NR1, NR2A, NR2B): Phosphorylation targets

AMPA receptor subunits (GluR1, GluR2): Synaptic trafficking modulation

Kinase Cross-Talk

PKCγ does not function in isolation but communicates with other kinases:

| Kinase | Interaction Type | Functional Outcome |
|--------|--------------|-----------------|
| PKA | Reciprocal inhibition | Balance plasticity |
| CaMKII | Synergistic | Enhanced LTP |
| GSK3β | Sequential | Tau phosphorylation |
| CDK5 | Cooperative | Development |

Disease Mechanisms Detailed

SCA14 Pathogenesis Cascade

The molecular cascade leading to Purkinje cell degeneration follows multiple pathways:

PRKCG mutation → Misfolded protein accumulation
↓
ER stress response activation
↓
Impaired membrane translocation
↓
Altered substrate phosphorylation
↓
Synaptic dysfunction at parallel fiber-Purkinje synapse
↓
Oxidative stress and mitochondrial dysfunction
↓
Progressive Purkinje cell death
↓
Cerebellar cortical atrophy
↓
Progressive cerebellar ataxia

Alzheimer's Disease Multiple Pathways

In Alzheimer's disease, PKCγ dysregulation affects multiple pathological processes:

APP processing dysregulation: Reduced α-secretase activity shifts APP cleavage toward amyloidogenic pathway

Tau hyperphosphorylation: Direct phosphorylation and activation of tau kinases promote neurofibrillary tangle formation

Synaptic failure: Impaired LTP and enhanced LTD disrupt synaptic integrity

Energy metabolism deficit: Mitochondrial dysfunction in neurons

Calcium dysregulation: Contributes to excitotoxicity vulnerability

Circadian disruption: PKCγ participates in circadian clock regulation

Comparison with Other PKC Isoforms

The PKC family contains multiple isoforms with distinct neuronal roles:

| Isoform | Brain Distribution | Primary Function | Neurodegenerative Disease Link |
|--------|---------------|-----------------|------------------|
| PKCα | Ubiquitous | Cell survival and proliferation | Alzheimer's, Parkinson's |
| PKCβ | Myelin, select neurons | Metabolism and cognition | Alzheimer's |
| PKCγ | Neurons only | Synaptic plasticity | SCA14 |
| PKCδ | Neurons | Pro-apoptotic signaling | Parkinson's |
| PKCε | Neurons | Neuroprotective | Alzheimer's |

Future Research Directions

Biomarker Development Priorities

Current research focuses on identifying reliable biomarkers:

Fluid biomarkers: CSF protein profiles including tau, NFL, neurogranin
Neuroimaging markers: Magnetic resonance spectroscopy, PET ligands for PKC
Electrophysiological markers: EEG patterns, evoked potentials
Clinical outcome measures: Standardized ataxia rating scales

Clinical Trial Pipeline

Several therapeutic approaches are advancing toward clinical trials:

First-in-human gene therapy trials for SCA14 planned within 5 years

PKC modulators for Alzheimer's disease in Phase 2/3 studies

Symptomatic treatments for ataxia in clinical testing

Biomarker validation studies in affected families

Critical Research Questions

Why are cerebellar Purkinje cells selectively vulnerable to PRKCG mutations?

How do different mutations result in such variable phenotypes?

Can early intervention with PKC modulators slow disease progression?

What is the role of PKCγ in normal cognitive function?

How does PKCγ dysfunction contribute to non-cerebellar neurodegenerative diseases?

Conclusion

PRKCG encodes a neuron-specific protein kinase of critical importance for cerebellar function, synaptic plasticity, and neuronal signaling throughout the brain. Pathogenic mutations in this gene cause SCA14, a progressive cerebellar ataxia characterized by selective Purkinje cell vulnerability. Beyond single-gene disorders, dysregulated PKCγ signaling contributes to the pathogenesis of Alzheimer's disease and Parkinson's disease through multiple mechanisms including amyloid precursor protein processing, tau phosphorylation, and synaptic dysfunction.

The neuron-specific expression pattern, clear disease associations, and central position in key neuronal signaling pathways make PRKCG an important gene both for understanding neurodegenerative disease mechanisms and for developing therapeutic interventions. Future research should focus on understanding selective vulnerability, developing disease-modifying therapies, and identifying biomarkers for early detection and clinical trial endpoints.

External Links

[NCBI Gene: PRKCG](https://www.ncbi.nlm.nih.gov/gene/5586)
[UniProt: P05129](https://www.uniprot.org/uniprot/P05129)
[OMIM: 176980](https://www.omim.org/entry/176980)
[GeneReviews: SCA14](https://www.ncbi.nlm.nih.gov/books/NBK1168/)
[PubMed: PRKCG neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PRKCG+neurodegeneration)

This page was updated to expand the NeuroWikievidence base for neurodegenerative disease research.

References

[Chen et al., PKCγ and SCA14 (2005)](https://doi.org/10.1093/brain/awh657)

[Banks et al., PKC in Alzheimer's (2015)](https://doi.org/10.3233/JAD-141083)

[Malmberg et al., PKCγ and pain (2003)](https://doi.org/10.1016/S0304-3959(03)00138-4)

[Jiang et al., Integrated Genomic Analysis in APOE4 Non-Carriers (2019)](https://pubmed.ncbi.nlm.nih.gov/31441725/)

[Kim et al., PKCγ deficiency and excitotoxic motoneuron death (2011)](https://pubmed.ncbi.nlm.nih.gov/21882104/)

[Schütt et al., SCA14 nonsense mutation (2019)](https://pubmed.ncbi.nlm.nih.gov/31158466/)

[Bird, GeneReviews: Spinocerebellar Ataxia Type 14 (2020)](https://pubmed.ncbi.nlm.nih.gov/20301573/)

[Verma et al., PKCγ in AD brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21886678/)

[Stefănescu et al., PKCγ Signaling in SCA14 (2020)](https://pubmed.ncbi.nlm.nih.gov/32082104/)

[Yedidia et al., PKC isoforms in Aβ dysfunction (2011)](https://pubmed.ncbi.nlm.nih.gov/21295268/)

[Salvatori et al., PKCγ phenotype variability (2015)](https://pubmed.ncbi.nlm.nih.gov/26190113/)

[Hironaga et al., SCA14 in Argentinian family (2023)](https://pubmed.ncbi.nlm.nih.gov/37101238/)

[Kleemen et al., Novel PRKCG variants (2022)](https://pubmed.ncbi.nlm.nih.gov/35760954/)

[Wood et al., Dutch PRKCG mutation (2006)](https://pubmed.ncbi.nlm.nih.gov/16547918/)

[Owashi et al., PKC regulation of NMDA receptor (2011)](https://pubmed.ncbi.nlm.nih.gov/21233508/)

[Post et al., PKC and synaptic plasticity (2008)](https://pubmed.ncbi.nlm.nih.gov/18614340/)

[Ohyawada et al., PKCγ in Purkinje cells (2018)](https://pubmed.ncbi.nlm.nih.gov/29605952/)

[Sacktor et al., PKM in LTP (1991)](https://pubmed.ncbi.nlm.nih.gov/1849793/)

[Bureau et al., PKCγ in neuropathic pain (2011)](https://pubmed.ncbi.nlm.nih.gov/21480652/)

[Ishigaki et al., PKCγ disease mechanisms (2017)](https://pubmed.ncbi.nlm.nih.gov/29035608/)

Pathway Diagram

The following diagram shows the key molecular relationships involving PRKCG — Protein Kinase C Gamma discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

PRKCG

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-prkcg
kg_node_id	PRKCG
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-270bea623c0a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-prkcg'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

31

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PRKCG — Protein Kinase C Gamma

PRKCG — Protein Kinase C Gamma

Introduction

PRKCG — Protein Kinase C Gamma

Introduction

Overview

Gene Structure and Evolution

Genomic Organization

Protein Domain Structure

Molecular Function

PKC Signaling Cascade

Key Substrates and Cellular Functions

Neuronal Processes Affected

Synaptic Plasticity

Ion Channel Regulation

Neuronal Development

Disease Associations

Spinocerebellar Ataxia Type 14 (SCA14)

Clinical Features

Pathogenic Mutations

Pathogenesis Mechanisms

Alzheimer's Disease

Amyloid Precursor Protein (APP) Processing

Tau Phosphorylation

Synaptic Dysfunction

Parkinson's Disease

Neuropathic Pain

Expression Pattern

Brain Regional Distribution

Cellular Expression

Therapeutic Implications

Target for Neurodegenerative Diseases

Clinical Trials and Drug Development

Animal Models

Knockout Mouse

Transgenic Models

Research Directions

Current Areas of Investigation

Unresolved Questions

Diagnosis and Genetic Testing

Diagnostic Approach

Differential Diagnosis

Genetic Counseling

Treatment and Management

Current Therapeutic Approaches

Emerging Therapies

Symptomatic Management Guidelines

Biochemical Properties

Enzyme Kinetics

Regulation Mechanisms

Post-Translational Modifications Table

Protein-Protein Interactions

Key Interacting Proteins

Kinase Cross-Talk

Disease Mechanisms Detailed

SCA14 Pathogenesis Cascade

Alzheimer's Disease Multiple Pathways

Comparison with Other PKC Isoforms

Future Research Directions

Biomarker Development Priorities

Clinical Trial Pipeline

Critical Research Questions

Conclusion

See Also

External Links

References

Pathway Diagram

💬 Discussion